Fig. 3From: Safety and efficacy of low-dose rt-PA with tirofiban to treat acute non-cardiogenic stroke: a single-center randomized controlled studyDistribution of the mRS at 90 days after the stroke. More patients in the rt-PA + T group (25/30, 83.3%) had favorable functional outcomes (mRS of 0–2) than the rt-PA group (18/30, 60.0%), P = 0.045Back to article page